Typhoid Fever (MONDO:0005619): Comprehensive Disease Characteristics Report

Summary

Typhoid fever is a systemic, potentially life-threatening febrile illness caused by the human-restricted bacterium Salmonella enterica subspecies enterica serovar Typhi (S. Typhi). It is transmitted by the fecal–oral route through water and food contaminated by the excreta of acutely infected patients or, critically, of chronic gallbladder carriers who constitute a persistent human reservoir. Unlike the classical templates for Mendelian disorders, typhoid is an infectious disease with no causal human gene; host genetics act only as susceptibility modifiers. The Global Burden of Disease Study 2017 estimated 14.3 million (95% UI 12.5–16.3) cases of typhoid and paratyphoid fevers in 2017 — a 44.6% decline from 1990 — with S. Typhi responsible for 76.3% of enteric-fever cases and a global case fatality of 0.95%. Burden is overwhelmingly concentrated in low- and middle-income countries (LMICs) of South Asia and sub-Saharan Africa, and incidence is highest in children under 15 years.

Mechanistically, the disease runs a well-characterized causal chain: ingested bacteria invade the small-intestinal epithelium and Peyer's-patch M cells via the SPI-1 type III secretion system, survive and replicate inside macrophages via the SPI-2 secretion system and the Vi capsular polysaccharide (which disturbs host autophagy and evades immune recognition), disseminate through the reticuloendothelial system (liver, spleen, bone marrow, gallbladder), and produce sustained bacteremia and a hyperinflammatory, endotoxin-driven fever. S. Typhi uniquely encodes a tripartite "typhoid toxin" (CdtB + PltA + PltB) that adds genotoxic and systemic effects. The most lethal complication is ileal (intestinal) perforation in weeks 2–3, carrying a pooled case-fatality of 15.4% among hospitalized cases.

Diagnosis still relies on blood culture (imperfect sensitivity), with rapid serologic tests offering only moderate accuracy. Treatment is increasingly constrained by multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains — leaving azithromycin and carbapenems (meropenem) as the mainstays — while typhoid conjugate vaccines (Vi-TT) deliver ~80% efficacy with durable multi-year protection, and improved water, sanitation and hygiene (WASH) remains the foundational preventive intervention. Chronic gallbladder carriage (2–5% of infections) not only sustains transmission but is quantitatively linked to gallbladder carcinoma (pooled OR ≈ 4.3).

1. Disease Information

Overview. Typhoid fever (enteric fever) is a systemic bacterial infection characterized by prolonged fever, bacteremia, and involvement of the reticuloendothelial system. It is caused by Salmonella enterica serovar Typhi, a Gram-negative, flagellated, facultatively intracellular bacillus that infects only humans. The closely related serovars Paratyphi A, B, and C cause a clinically similar but generally milder "paratyphoid fever"; together they constitute "enteric fever."

Key identifiers. - MONDO: MONDO:0005619 (typhoid fever) - ICD-10: A01.0 (Typhoid fever); ICD-11: 1A07 (Typhoid fever) - MeSH: D014435 (Typhoid Fever) - SNOMED CT: 4834000 (Typhoid fever) - NCBI Taxonomy (pathogen): Salmonella enterica subsp. enterica serovar Typhi — txid90370 - OMIM/Orphanet: Not a Mendelian disease; no OMIM disease entry. Host susceptibility loci have been mapped (see Section 4).

Synonyms / alternative names. Enteric fever (when grouped with paratyphoid), typhoid, "slow fever," historically "gastric fever" and "nervous fever."

Data provenance. The information in this report is derived almost entirely from aggregated disease-level resources — systematic reviews, meta-analyses, randomized controlled trials, GBD modeling, and controlled human infection (challenge) studies — rather than from individual EHR records.

2. Etiology

Primary cause (infectious). The sole causal agent is S. Typhi (Finding F001). Transmission is fecal–oral via contaminated water and food. The human-restricted nature of the pathogen means the reservoir is entirely human — acute cases and chronic carriers.

Environmental / behavioral risk factors. Inadequate water, sanitation and hygiene (WASH) is the dominant modifiable driver. A meta-analysis of 27 case-control studies quantified limited hygiene (OR 2.26, 95% CrI 1.38–3.64) and untreated drinking water (OR 1.96) as risk factors (PMID: 37644449; Finding F011). Field studies add contaminated drinking water, poor sanitation, and street-food consumption as severity-associated exposures (PMID: 42602150). In Nairobi informal settlements, use of a shared flush toilet was independently associated with infection (aOR 2.42, 95% CI 1.69–3.47), as was age 5–16 years (PMID: 42778887). Additional host/behavioral factors include young age (school-age children), living in endemic/crowded urban slums, and — for the carrier state — gallstones, biliary abnormalities, and a cholesterol-rich diet.

Genetic risk factors (host). Typhoid is not a genetic disease, but host genetic susceptibility has been demonstrated. A controlled human challenge study genotyped volunteers and identified variants associated with enteric-fever susceptibility (PMID: 35254093; Finding F007). Classical literature also implicates HLA class II alleles, TLR pathway variants, and the CFTR locus, though these are modifiers of modest effect rather than causal variants.

Protective factors. Vaccination (typhoid conjugate vaccine — Section 13) and improved household WASH are the principal protective factors; a Dhaka slum cohort (n = 98,087) found improved household WASH associated with a 38% reduction in typhoid risk (adjusted HR 0.62, 95% CI 0.49–0.78) (PMID: 37983081; Finding F011). Pre-existing immunity from prior exposure also protects.

Gene–environment interaction. The dominant interaction is between environmental exposure dose (WASH-mediated) and host immune competence; a persistent post-infection "convalescent" transcriptional signature may mark hosts genetically or temporarily unable to mount effective immunity, predisposing to relapse or the carrier state (PMID: 20018727; Finding F007).

3. Phenotypes

Typhoid presents with an insidious onset of sustained fever over the first week, progressing over 2–3 weeks if untreated. In a retrospective series of 305 confirmed cases, fever was universal (100%), followed by abdominal pain (62.0%), loss of appetite (43.3%), headache (40.3%), diarrhea (34.8%), and constipation (24.3%); hepatomegaly (30.1%) and splenomegaly (22.3%) were common (PMID: 41246786).

Onset: subacute/insidious (days). Severity: variable — from mild self-limited febrile illness to fulminant disease with perforation, shock, and death. Progression: progressive over weeks if untreated, then resolving (with treatment) or complicated. Quality-of-life impact: substantial acute morbidity (mean hospital stay for perforation 18.4 days; Finding F006) and major economic burden — in hospitalized Kenyan children, median societal cost per admission US$96.95, with up to ~24–27% of poorest households facing catastrophic health expenditure (PMID: 42580776).

4. Genetic/Molecular Information

Causal human genes: None. Typhoid is an infectious disease; there is no causal germline mutation.

Host susceptibility loci: Controlled human infection modeling has identified genetic variants associated with enteric-fever susceptibility (PMID: 35254093). Candidate genes in the broader literature include HLA-DRB1/DQB1, TLR4/TLR5, SLC11A1 (NRAMP1), and CFTR (the CFTR protein has been proposed as an intestinal entry receptor for S. Typhi). These are modifier/susceptibility loci, not Mendelian causes.

Pathogen genetic determinants (the relevant "molecular" biology). Virulence is encoded on Salmonella pathogenicity islands (SPIs) and the viaB locus: - SPI-1 — invasion-associated type III secretion system (T3SS-1). - SPI-2 — intracellular survival T3SS-2. - SPI-7 / viaB locus — encodes the Vi capsular polysaccharide (tviA–E, vexA–E). - Typhoid toxin operon — cdtB, pltA, pltB (Finding F002).

Antimicrobial-resistance genetics (the clinically decisive molecular story). Resistance is driven by plasmid acquisition and clonal spread of the H58 lineage. Emerging cephalosporin resistance in India results from bla (e.g., blaCTX-M-15) acquisition via plasmids from other bacteria (PMID: 40208005; Finding F005). Fluoroquinolone resistance arises from gyrA/parC QRDR mutations. XDR strains combine resistance to first-line drugs, fluoroquinolones, and third-generation cephalosporins (PMID: 41550837).

Epigenetic / chromosomal abnormalities: Not applicable to the human host in the Mendelian sense. (Bacterial DNA methylation regulates virulence gene expression but is outside the human-disease-gene framework.)

5. Environmental Information

Environmental factors. Contaminated water supplies and inadequate sewage/sanitation infrastructure are the principal environmental determinants; fecal contamination of drinking water is the classic transmission route. Wastewater surveillance detects S. Typhi in the community and correlates with clinical incidence — each 10-fold increase in typhoid incidence gave 2.43× higher odds of S. Typhi wastewater detection (PMID: 42419341).

Lifestyle factors. Street-food consumption, unsafe water handling and storage, and shared sanitation facilities increase risk (PMID: 42602150; PMID: 42778887). A cholesterol-rich diet favors gallbladder carriage (PMID: 39636114).

Infectious agent. Salmonella enterica subsp. enterica serovar Typhi (NCBI Taxon 90370) — the necessary and sufficient cause. CHEBI-relevant chemical entities: lipopolysaccharide/endotoxin (CHEBI:16412), cholesterol (CHEBI:16113).

6. Mechanism / Pathophysiology

Ordered causal chain

1. Ingestion of S. Typhi in fecally contaminated water/food → bacteria survive gastric acid and reach the small intestine. (demonstrated)
2. SPI-1 T3SS-1–mediated invasion of intestinal epithelium and Peyer's-patch M cells in the terminal ileum → bacterial translocation across the mucosa. (demonstrated)
3. Uptake by macrophages/dendritic cells; S. Typhi resides in the Salmonella-containing vacuole (SCV) and uses SPI-2 T3SS-2 and the Vi capsule to survive intracellularly. The Vi capsule decreases macrophage autophagy by down-regulating Nod2 and Galectin-8 (↑LC3-II, ↓p62 in Vi mutants) → enhanced intracellular survival (PMID: 39732413; Finding F010). (demonstrated)
4. Immune evasion / modulation: Vi paradoxically binds the human C-type lectin DC-SIGN to modulate phagocytosis (PMID: 36286551); relative to S. Typhimurium, S. Typhi induces greater SPI-1–dependent inflammasome activation (caspase-1, IL-1β, pyroptosis) in monocyte-derived macrophages → hyperinflammatory bacteremic state (PMID: 32387390; Finding F010). (demonstrated in vitro)
5. Reticuloendothelial dissemination: infected macrophages carry bacteria to mesenteric lymph nodes, then via lymphatics/blood to liver, spleen, bone marrow, and gallbladder → primary/secondary bacteremia. (inferred from classical pathology + demonstrated tropism)
6. Sustained bacteremia + endotoxin (LPS)–driven cytokine response → prolonged stepwise fever, and a reproducible peripheral-blood transcriptional signature during acute disease (PMID: 20018727; Finding F007). (demonstrated)
7. Typhoid toxin action: S. Typhi expresses CdtB within the SCV, secreted in outer-membrane vesicles; PltA/PltB deliver the genotoxic CdtB to target cells via retrograde Golgi transport → DNA damage, cell-cycle arrest, and contribution to systemic symptoms (PMID: 18191792, PMID: 23869968; Finding F002). (demonstrated in vitro/in vivo)

Branch A — acute severe disease: Hyperplasia and necrosis of Peyer's-patch lymphoid tissue in the terminal ileum → mucosal ulceration → ileal perforation (weeks 2–3) → peritonitis, sepsis, death (pooled CFR 15.4%; Finding F006).

Branch B — chronic carriage: Gallbladder colonization, favored by gallstones and cholesterol-rich diet, with CsgD-regulated curli/cellulose biofilm formation → asymptomatic intermittent shedding (2–5% of infections), antibiotic tolerance, transmission, and long-term gallbladder carcinoma risk (PMID: 41335321, PMID: 39720794, PMID: 24612190; Findings F003, F008).

Mechanism map (ASCII)

 Ingestion (fecal-oral)
│
▼
 Ileal epithelium / M cells ──SPI-1 T3SS-1──► invasion
│
▼
 Macrophage SCV ──SPI-2 + Vi capsule──► intracellular survival
│        (↓autophagy via Nod2/Galectin-8; DC-SIGN binding)
▼
 Reticuloendothelial spread (liver, spleen, marrow, gallbladder)
│
├──► Sustained bacteremia + LPS ──► fever, blood transcriptional signature
│
├──► Typhoid toxin (CdtB/PltA/PltB) ──► genotoxicity, systemic effects
│
├── BRANCH A ──► Peyer's-patch necrosis ──► ILEAL PERFORATION (wk 2-3) ──► death
│
└── BRANCH B ──► gallbladder biofilm on gallstones ──► CHRONIC CARRIAGE ──► gallbladder cancer

Ontology suggestions. GO biological processes: GO:0009405 (pathogenesis), GO:0052167 (modulation of host immune response), GO:0006909 (phagocytosis), GO:0016236 (macroautophagy), GO:0002526 (acute inflammatory response). Cell types (CL): CL:0000235 (macrophage), CL:0000451 (dendritic cell), CL:0000236 (B cell), CL:0000084 (T cell), CL:0002270 (M cell / microfold cell). Subcellular (GO CC): GO:0005764 (lysosome), GO:0005794 (Golgi). Chemical entities (CHEBI): CHEBI:16412 (LPS), CHEBI:16113 (cholesterol).

7. Anatomical Structures Affected

• Primary organs: terminal ileum / small intestine (UBERON:0002116; Peyer's patches UBERON:0011156), mesenteric lymph nodes (UBERON:0002509).
• Reticuloendothelial system: liver (UBERON:0002107; hepatomegaly ~30%), spleen (UBERON:0002106; splenomegaly ~22%), bone marrow (UBERON:0002371), gallbladder (UBERON:0002110 — carrier niche).
• Secondary/complication sites: peritoneum (perforation → peritonitis), CNS (typhoid encephalopathy), skin (rose spots), and — in chronic carriers — gallbladder neoplasia.
• Body systems: digestive, lymphatic/reticuloendothelial, hematopoietic, and (severe cases) nervous and cardiovascular systems.
• Tissue/cell level: intestinal epithelium and M cells (CL:0002270); macrophages (CL:0000235) as the primary intracellular niche and key determinant of disease progression (PMID: 40095029); lymphocytes (T and B cells) recruited to the gallbladder in carriage (mouse model, PMID: 31575775).
• Subcellular: the Salmonella-containing vacuole, lysosome, and Golgi (typhoid-toxin retrograde transport).
• Lateralization: not applicable (systemic disease); ileal lesions are segmental, antimesenteric.

8. Temporal Development

• Onset: insidious/subacute; incubation typically 6–30 days (usually ~1–2 weeks), dose-dependent.
• Classic weekly progression (untreated):
• Week 1 — rising stepwise fever, headache, malaise, relative bradycardia.
• Week 2 — sustained high fever, abdominal pain, rose spots, hepatosplenomegaly, "typhoid state" (apathy/delirium).
• Week 3 — risk of ileal perforation and intestinal hemorrhage, peritonitis, shock. Perforation cases nearly all present in the second week of infection (PMID: 34652510).
• Week 4+ — gradual resolution if survived.
• Duration: typically self-limited to weeks with treatment; relapse in ~5–10% after apparent recovery. Chronic carriage (>12 months of shedding) develops in 2–5% — a lifelong reservoir state (Finding F003).
• Critical intervention window: early antimicrobial therapy (first week) prevents most complications; the peri-perforation window (week 2–3) is the critical period for surgical intervention.

9. Inheritance and Population

Inheritance: Not applicable (infectious, non-heritable). Host susceptibility is multifactorial/polygenic with modest-effect loci.

Epidemiology (Findings F001, F009).

Geographic distribution: endemic across South Asia (India, Pakistan, Bangladesh, Nepal), sub-Saharan Africa, and Southeast Asia; sporadic/travel-associated in high-income countries. Typhoid shows strong spatial-temporal clustering — incidence-rate ratio 4.9 in the innermost ring around index cases within 28 days, supporting targeted "ring" vaccination (PMID: 38913735; Finding F011).

Age/sex: Incidence highest in children <15 years (school-age); a slight male predominance is often reported (e.g., male-to-female ~1.4:1 in a Lahore cohort, PMID: 41246786). Chronic carriage is more common in older adults, women, and those with gallstones.

10. Diagnostics

Reference standard: Blood culture (and, more sensitively, bone marrow culture). Blood culture positivity is imperfect (e.g., 61–78% in various cohorts: PMID: 31884434, PMID: 41246786), reduced further by prior antibiotics.

Laboratory clues: leukopenia, eosinopenia, anemia; elevated liver transaminases. Anemia is prominent in perforation cases (62.5% in a Burkina Faso series, PMID: 28406420).

Rapid diagnostic tests (RDTs) / serology (moderate accuracy): A Cochrane review of 37 studies (5,080 participants) found TUBEX sensitivity 78% / specificity 87%; Typhidot sensitivity ~78–84% / specificity ~77–79%; Test-It Typhoid (KIT) sensitivity 69% / specificity 90% — all only moderately accurate (PMID: 28545155). The Widal test performs poorly and is not recommended alone. A Bayesian latent-class network analysis found IgM-based tests outperform IgG counterparts, with lateral-flow IgG and Reverse Passive Hemagglutination performing best in South Asian pediatric populations (PMID: 31067228).

Emerging biomarker assays: Plasma IgA responses to HlyE + LPS distinguished acute typhoid from other bacteremic illnesses (AUC 0.95; sensitivity 90%, specificity 92%) (PMID: 30020426) — a promising next-generation diagnostic.

Molecular: Multiplex qPCR targeting ttr, staG, tviB (used in wastewater surveillance, PMID: 42419341); gene markers invA (genus), phsB (H₂S), and tviA (S. Typhi-specific) for identification (PMID: 42584516).

Imaging: Erect abdominal radiograph showing pneumoperitoneum (86.7% of pediatric perforation cases, PMID: 34652510) for the perforation complication; ultrasound for hepatosplenomegaly and gallstones.

Genetic/omics diagnostics: Not applicable for host diagnosis. Pathogen whole-genome sequencing is used for AMR surveillance and outbreak tracing.

Differential diagnosis: malaria, dengue, rickettsial disease, leptospirosis, brucellosis, amebic liver abscess, and other causes of prolonged fever in endemic areas.

11. Outcome/Prognosis

• Mortality: With prompt appropriate antibiotics, case-fatality is low (global ~0.95%, PMID: 30792131). Untreated, historical mortality reached 10–30%.
• Ileal perforation (principal lethal complication; Finding F006): Systematic review of 42 reports — 4,626 cases, 706 deaths, pooled CFR 15.4% (95% CI 13.0–17.8%), mean hospital stay 18.4 days (PMID: 24743649). Single-center CFRs range 17–30% (PMID: 28406420, PMID: 24858189); pediatric perforation mortality ~26.7%, reaching 100% with three or more perforations (PMID: 34652510, PMID: 24858189).
• Prognostic factors: number of perforations, severity of peritonitis, delay to surgery (>2 h operative time), tachycardia/tachypnea at presentation, and serum potassium (dominant predictor of prolonged stay in a pediatric ML model, PMID: 42048896).
• Other complications: GI hemorrhage, typhoid encephalopathy, myocarditis, relapse (~5–10%), chronic carriage (2–5%), and long-term gallbladder carcinoma (pooled OR 4.28; Finding F008).
• Recovery: most treated patients recover fully; carriage and gallbladder-cancer risk are the key long-term sequelae.

12. Treatment

Pharmacotherapy (empiric, guided by local resistance).

Resistance landscape (Finding F005): MDR = resistance to ampicillin, chloramphenicol, and TMP-SMX; XDR additionally resists fluoroquinolones and third-generation cephalosporins, first reported in Pakistan and spreading (largely H58 lineage). In one XDR cohort, all isolates resisted ceftriaxone, ciprofloxacin, and first-line agents; meropenem and azithromycin remained 100% and 96.9% susceptible (PMID: 41550837). By 2021, MDR and XDR proportions reached 14.7% and 43.4% in one Pakistani study (PMID: 38710290). Emerging cephalosporin resistance in India arises from plasmid-borne bla genes (PMID: 40208005). Combination regimens (e.g., meropenem + azithromycin) are used for refractory XDR pediatric cases (PMID: 38404085).

Surgical/interventional: For perforation — exploratory laparotomy with simple two-layer closure, ileal resection with anastomosis, or ileostomy, plus peritoneal lavage (NCIT: laparotomy C15320). Timing is critical; operative delay worsens outcome.

Supportive care: fluid/electrolyte resuscitation, antipyretics, nutrition, and correction of hypokalemia.

Experimental / emerging: Anti-virulence and quorum-sensing (LuxS/AI-2) inhibitors and quorum-quenching biotherapeutics are under investigation but remain preclinical (PMID: 42530739, PMID: 42250148); phage therapy and multi-omics/AI-guided target discovery are being explored.

Pharmacogenomics: No established host pharmacogenomic guidance specific to typhoid therapy.

13. Prevention

Primary prevention — vaccination (Finding F004). Typhoid conjugate vaccines (Vi-TT / Vi-CRM197) are the leading tool. In the Malawi phase-3 RCT (28,130 children), a single dose of Vi-TT gave 78.3% efficacy with durable protection over ~4.3 years across all age groups including infants (PMID: 38281499). A meta-analysis of 4 trials (111,481 children) found the risk of blood-culture-confirmed typhoid after Vi-TT was 0.18 vs controls (~80% efficacy) (PMID: 40788116); a test-negative design estimated 80.3% effectiveness (PMID: 36442498). Protection may wane 3–5 years post-vaccination (especially in those vaccinated <2 years), and evidence increasingly supports a booster dose at a longer interval (PMID: 42556475). WHO recommends mass campaigns for children 9 months–15 years followed by routine infant introduction. Older Vi-polysaccharide and Ty21a live-oral vaccines exist but are less suited to young children.

Primary prevention — WASH (Finding F011). Safe drinking water, improved sanitation, and hand hygiene reduce transmission; improved household WASH cut typhoid risk 38% (PMID: 37983081). WASH and vaccination are complementary.

Secondary prevention: early diagnosis/treatment; carrier detection and treatment (and cholecystectomy for carriers with gallstones) removes reservoirs. Wastewater surveillance enables early outbreak detection and vaccine-impact monitoring (PMID: 42419341); ring vaccination around cases is supported by spatial clustering (PMID: 38913735).

Tertiary prevention: prompt surgical management of perforation; antimicrobial stewardship to preserve azithromycin/carbapenems.

Public health: sanitation infrastructure, safe food handling (street-food hygiene), health education. Community KAP gaps are large — in Lilongwe, only 8.2% had adequate typhoid knowledge and 16.7% were aware of TCV (PMID: 41783922), underscoring the need for education.

14. Other Species / Natural Disease

S. Typhi is strictly human-restricted — there is no natural animal reservoir or naturally occurring typhoid fever in other species. This host restriction reflects co-evolution of virulence factors (including host-adapted typhoid toxin; PMID: 28993610) with the human host.

• Zoonotic potential: none for S. Typhi (contrast with non-typhoidal Salmonella, which are zoonotic).
• Comparative biology: related host-adapted serovars cause analogous systemic disease in animals (e.g., S. Gallinarum in poultry, S. Dublin in cattle, S. Choleraesuis in pigs), providing comparative models of Salmonella host adaptation. Pigs infected with S. Typhimurium show shedding-level-dependent cytokine/transcriptomic phenotypes relevant to carriage biology (PMID: 24632525).
• Orthologous virulence loci (SPI-1, SPI-2) are conserved across Salmonella serovars.

15. Model Organisms

Because S. Typhi does not naturally infect other species, modeling relies on surrogates:

Databases: MGI (mouse), and Salmonella genomic resources (EnteroBase, BV-BRC) for pathogen genetics.

Key Findings (with statistical evidence)

F001 — Human-restricted S. Typhi causes a large LMIC-concentrated burden

WHO EMR review: 5.57–9.23 million cases and 46,200–163,000 deaths annually, mainly in LMICs; sentinel median incidence 140/100,000 py; highest in children <15 y. "Annually, there are 5.57 to 9.23 million typhoid fever cases and 46,200 to 163,000 associated deaths, mainly in low- and middle-income countries." (PMID: 42413480).

F002 — Unique tripartite "typhoid toxin"

CdtB (genotoxic subunit) + PltA/PltB (pertussis-toxin homologs) assemble into a holotoxin expressed within the SCV and secreted in outer-membrane vesicles; retrograde Golgi transport is required for DNA damage. "PltA and PltB are required for the delivery of CdtB from an intracellular compartment to target cells via autocrine and paracrine pathways… this toxin, which we have named 'typhoid toxin'" (PMID: 18191792); "…expresses its CDT (named as Typhoid toxin) only in the Salmonella-containing vacuole (SCV) of infected cells" (PMID: 23869968).

F003 — Chronic gallbladder carriage sustains transmission

2–5% of infections become chronic carriers; gallstones + CsgD-regulated biofilm enhance persistence and antibiotic resistance. "Chronic carriers, accounting for 2-5% of infections, play a crucial role in disease transmission… often asymptomatic but intermittently shed bacteria"; "Gallstones are strongly associated with the chronic carrier state, providing a niche for bacterial biofilm formation…" (PMID: 41335321).

F004 — Typhoid conjugate vaccine ~80% efficacious, durable

Meta-analysis of 4 trials (111,481 children): RR 0.18 after Vi-TT. "Four trials with 111 481 children found the risk of blood culture-confirmed typhoid fever after Vi-TT to be 0.18 compared with nontyphoid vaccines." (PMID: 40788116); field effectiveness 80.3% (PMID: 36442498); durable ≥4 years (PMID: 38281499).

F005 — MDR/XDR narrows treatment to azithromycin + carbapenems

"All isolates were resistant to ceftriaxone, ciprofloxacin, and first-line agents; meropenem and azithromycin remained 100% and 96.9% susceptible." (PMID: 41550837); "New strains in India show resistance to third-generation cephalosporins due to plasmid acquisition from other bacteria" (PMID: 40208005).

F006 — Ileal perforation is the major lethal complication

"a total of 4,626 hospitalized typhoid intestinal perforation cases and 706 deaths were recorded (CFR = 15·4%; 95% CI 13·0%-17·8%)" (PMID: 24743649).

F007 — Reproducible blood transcriptional signature, persistent convalescent signature

"typhoid fever induced a distinct and highly reproducible signature in the peripheral blood that changed during treatment and convalescence"; the persistent convalescent signature may mark hosts "more susceptible to reinfection, relapse, or the establishment of a carrier state." (PMID: 20018727); susceptibility variants via challenge genotyping (PMID: 35254093).

F008 — Chronic carriage linked to gallbladder carcinoma

"The overall OR for chronic S. typhi carrier state was 4.28 (95% CI: 1.84-9.96)." (PMID: 24612190).

F009 — GBD 2017 authoritative burden

"Globally, 14·3 million (95% UI 12·5-16·3) cases of typhoid and paratyphoid fevers occurred in 2017, a 44·6% decline from 25·9 million in 1990."; "Salmonella enterica serotype Typhi caused 76·3% of cases… global case fatality of 0·95% in 2017." (PMID: 30792131).

F010 — Vi capsule + SPI-1 drive macrophage survival and hyperinflammation

"Vi capsule of S. Typhi decreased autophagy of macrophages to increase its survival in host cells by decreasing the expression of Nod2 and Galectin-8." (PMID: 39732413); "S. Typhi, relative to its non-typhoidal counterpart, S. Typhimurium, induces greater SPI-1-dependent inflammasome activation in monocyte-derived macrophages" (PMID: 32387390).

F011 — WASH is a modifiable risk factor; typhoid clusters spatially

"Pooled estimates of limited hygiene (OR = 2.26, 95% CrI: 1.38 to 3.64), untreated water (OR = 1.96…)" (PMID: 37644449); "The IRR in this innermost cluster was 4.9" (PMID: 38913735); improved household WASH → 38% risk reduction (PMID: 37983081).

Mechanistic Model / Interpretation

The findings cohere into a single narrative in which the pathogen's cellular tropism dictates both acute disease and the chronic reservoir. S. Typhi's defining evolutionary innovations — the Vi capsule and the typhoid toxin — are the molecular reasons it behaves so differently from non-typhoidal Salmonella: the Vi capsule permits an intracellular lifestyle (by suppressing autophagy and modulating DC-SIGN-mediated phagocytosis) that would be paradoxical for a normally anti-phagocytic surface structure, while the exaggerated SPI-1 inflammasome response explains the hyperinflammatory bacteremic state clinically seen as prolonged high fever (F010). The macrophage is therefore the pivotal cell (CL:0000235): its permissiveness allows reticuloendothelial dissemination, and the balance of its inflammatory response shapes whether disease is self-limited, fulminant (→ perforation, F006), or transitions to carriage.

The carriage branch (F003, F008) transforms an acute infection into a lifelong public-health problem: gallstone-associated biofilm creates an antibiotic-tolerant niche whose intermittent shedding sustains community transmission and whose chronic inflammation drives a >4-fold increase in gallbladder-cancer risk. This links an infectious disease to an oncologic outcome — a rare and important causal chain.

At the population level, the epidemiologic findings (F001, F009, F011) show the disease is environmentally gated: burden tracks WASH deficits and clusters spatially, so both WASH investment and geographically targeted vaccination are rational levers. The therapeutic findings (F005) and preventive findings (F004) frame the current crisis and its solution: as XDR strains erode the antibiotic armamentarium, the conjugate vaccine (durable ~80% efficacy) shifts control from cure toward prevention.

Evidence Base

Limitations and Knowledge Gaps

1. No human causal genetics. Because typhoid is infectious, the template's genetic sections (causal genes, ACMG variant classification, inheritance, penetrance) are largely not applicable; host susceptibility loci are of modest, incompletely mapped effect.
2. Burden uncertainty. GBD estimates carry wide uncertainty intervals and depend on modeling; blood-culture under-ascertainment biases incidence downward. Serosurveys and wastewater surveillance are emerging but not standardized.
3. Mechanistic evidence is largely in vitro / surrogate-model. Key macrophage mechanisms (Vi–autophagy, SPI-1 inflammasome) derive from cell lines; carriage biology relies on S. Typhimurium mouse models that lack Vi and typhoid toxin, limiting direct translation.
4. Diagnostics remain suboptimal. Blood culture is insensitive and slow; RDTs are only moderately accurate; the promising IgA/HlyE assay is not yet widely deployed.
5. Vaccine durability. Waning immunity 3–5 years post-TCV and optimal booster strategy are unresolved.
6. Paratyphoid gap. S. Paratyphi A causes a growing share of enteric fever and is not covered by current TCVs.

Proposed Follow-up Experiments / Actions

1. Deploy next-generation diagnostics: validate and scale the IgA anti-HlyE/LPS assay (PMID: 30020426) and standardize wastewater qPCR surveillance for real-time transmission monitoring and vaccine-impact evaluation.
2. Define human host-susceptibility architecture: expand challenge-cohort GWAS (PMID: 35254093) and connect it to the persistent convalescent transcriptional signature to predict carriage/relapse risk.
3. Test carriage-eradication strategies: anti-biofilm/CsgD-targeted and quorum-quenching agents in gallbladder-carriage models, with the explicit endpoint of interrupting transmission and reducing gallbladder-cancer risk.
4. Optimize vaccination policy: trials of TCV booster timing (favoring longer intervals, PMID: 42556475) and evaluation of ring vaccination exploiting spatial clustering (IRR 4.9, PMID: 38913735).
5. Preserve last-line antibiotics: implement antimicrobial-stewardship programs and genomic AMR surveillance (H58 lineage, bla plasmid tracking) to protect azithromycin and carbapenems.
6. Advance bivalent/multivalent vaccines covering S. Paratyphi A and iNTS to close the enteric-fever coverage gap (PMID: 42566676).

Report compiled from 11 confirmed findings and 59 reviewed papers across 5 investigation iterations. Evidence types span human clinical (RCTs, cohorts, meta-analyses), controlled human infection, model organism (mouse), and in vitro mechanistic studies.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.3.0rc1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0002027 (1 mention) - the report calls it "Symptom"; HP calls it Abdominal pain
• HP:0002039 (1 mention) - the report calls it "Symptom"; HP calls it Anorexia
• HP:0002315 (1 mention) - the report calls it "Symptom"; HP calls it Headache
• HP:0002014 (1 mention) - the report calls it "Symptom"; HP calls it Diarrhea
• HP:0002019 (1 mention) - the report calls it "Symptom"; HP calls it Constipation
• HP:0002240 (1 mention) - the report calls it "Clinical sign"; HP calls it Hepatomegaly
• HP:0001744 (1 mention) - the report calls it "Clinical sign"; HP calls it Splenomegaly
• HP:0011276 (1 mention) - the report calls it "Abnormality of skin morphology"; HP calls it Vascular skin abnormality
• CL:0002270 (2 mentions) - the report calls it "M cell / microfold cell", "M cells", "Tissue/cell level: intestinal epithelium and M cells"; CL calls it type EC2 enteroendocrine cell
• UBERON:0002110 (1 mention) - the report calls it "carrier niche"; UBERON calls it gallbladder

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0009405 (obsolete pathogenesis) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0001882 (1 mention) - the report calls it "Leukopenia"; HP calls it Decreased total leukocyte count, and lists "Leukopenia" among its other names
• CHEBI:16412 (2 mentions) - the report calls it "LPS"; CHEBI calls it lipopolysaccharide, and lists "LPS" among its other names
• GO:0009405 (1 mention) - the report calls it "pathogenesis"; GO calls it obsolete pathogenesis
• GO:0052167 (1 mention) - the report calls it "modulation of host immune response"; GO calls it symbiont-mediated perturbation of host innate immune response, and lists "modulation of host innate immune response" among its other names
• GO:0005794 (1 mention) - the report calls it "Golgi"; GO calls it Golgi apparatus, and lists "Golgi" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• CL:0000235 - called "macrophage", "macrophages"
• CL:0002270 - called "M cell / microfold cell", "M cells", "Tissue/cell level: intestinal epithelium and M cells"